Application of a PEBP4 gene and its siRNA in the preparation of a drug or reagent for treating porcine reproductive and respiratory syndrome
By constructing and transfecting PEBP4-Flag plasmid, its role in pig reproduction and respiratory syndrome virus was studied, and it was found that PEBP4 protein promotes viral replication and inhibits its expression through siRNA to effectively control viral infection, solving the lack of the existing technology Effective treatment of pig reproductive and respiratory syndrome problems provides new treatment options.
Patent Information
- Application Number
- CN202410741957.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-07
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2044-06-07
AI Technical Summary
Currently, there is a lack of effective treatments for the proliferation of pig reproductive and respiratory syndrome virus (PRRSV), especially the role of PEBP4 protein in this virus has not been studied, resulting in a lack of treatment pathways.
By constructing and transfecting the PEBP4-Flag plasmid, overexpression of PEBP4 protein was achieved and siRNA was designed to interfere with PEBP4 gene expression to inhibit its expression in cells, thereby studying its effect on PRRSV replication.
It was found that overexpressing PEBP4 protein promotes PRRSV replication, and knocking down PEBP4 expression through siRNA can effectively control PRRSV infection, indicating that PEBP4 protein is an important host target for PRRSV replication, and provides new drugs or reagents for the treatment of pig reproductive and respiratory syndrome. .
Smart Images

Figure CN118516408B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of protein engineering, and in particular relates to an application of a PEBP4 gene and its siRNA in preparing a medicine or reagent for treating porcine reproductive and respiratory syndrome. Background Art
[0002] Porcine reproductive and respiratory syndrome (PRRS) is one of the major infectious diseases affecting the world's pig industry. Porcine reproductive and respiratory syndrome virus (PRRSV) is the pathogen that causes PRRS, which mainly causes abortion, stillbirth, mummified fetuses in sows, and respiratory diseases in pigs of all ages.
[0003] Phosphatidylethanolamine-binding protein 4 (PEBP4) is a member of the phosphatidylethanolamine-binding protein family. The PEBP family is a superfamily with more than 400 members. Family members have similar domains, with two small β-folds connected to both sides of a large β-fold, and two α-helices connected to the C-terminus. There is a highly conserved phosphate binding site in the domain, which plays an important role in the function of the PEBP family. The PEBP4 family is highly conserved in human and bacterial evolution, and different subfamilies have different biological functions, and the homology between different species is low.
[0004] A large number of studies have shown that PEBP4 is highly expressed in various cancer tissue cells and participates in multiple signaling pathways. PEBP4 is involved in the activation of the AKT signaling pathway, and it seems to be an important factor in the activation of the AKT signaling pathway in cancer cells. The AKT signaling pathway is activated in a variety of tumor cells, affecting the occurrence and development of tumors and poor prognosis. Yu and Zhang et al. found that PBEP4 activated the AKT signaling pathway by promoting phosphorylation of the AKT Ser473 site (D. Zhang, Y. Dai, Y. Cai, et al. PEBP4 promoted the growth and migration of cancer cells in pancreatic ductal adenocarcinoma [J]. Journal, 2016, 37 (Issume): 1699-1705.). In addition, Li et al. found that hypoxia can increase the accumulation of ROS and thus activate the AKT pathway, but downregulating PEBP4 can inhibit hypoxia-induced AKT activation. (Y.Zhao, X.Hu, Y.Liu, et al.ROS signaling under metabolic stress: cross-talk between AMPK and AKT pathway[J].Journal, 2017, 16(Issume):79.) In addition, in the radiotherapy of cancer, PEBP4 acts as a signaling molecule to help ROS mediate the phosphorylation of AKT, thereby improving the survival rate of cancer cells and their ability to resist apoptosis and radiation. The above results show that the activation of the AKT signaling pathway in tumor cells and the resistance of cells to chemotherapy and radiotherapy are highly correlated with the PEBP4 protein.
[0005] However, there is currently no research on the effect of PEBP4 protein on porcine reproductive and respiratory syndrome virus. Therefore, it is urgent to verify the effect of PEBP4 on the proliferation of PRRSV and provide new approaches and methods for the treatment of porcine reproductive and respiratory syndrome virus. Summary of the invention
[0006] In view of this, the object of the present invention is to provide an application of a PEBP4 gene and its siRNA in the preparation of a drug or reagent for treating porcine reproductive and respiratory syndrome.
[0007] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0008] The present invention provides the use of overexpressed PEBP4 protein in promoting the proliferation of PRRSV.
[0009] Preferably, the method for overexpressing PEBP4 protein comprises the following steps:
[0010] A plasmid for overexpressing PEBP4 protein was constructed, and the plasmid was transfected into cells to achieve overexpression of PEBP4 protein.
[0011] Preferably, the plasmid is PEBP4-Flag, and the PEBP4-Flag uses pCAGGS as the initial vector, and a gene fragment expressing the PEBP4 protein is cloned between the SacI and NheI restriction sites on the pCAGGS vector.
[0012] The present invention also provides a plasmid for overexpressing PEBP4 protein. The plasmid is PEBP4-Flag. The PEBP4-Flag uses pCAGGS as an initial vector, and a gene fragment expressing PEBP4 protein is cloned between the SacI and NheI restriction sites on the pCAGGS vector.
[0013] The invention also provides application of the plasmid in promoting the proliferation of PRRSV.
[0014] The present invention also provides the use of a PEBP4 protein expression inhibitor in the preparation of a medicine or reagent for treating porcine reproductive and respiratory syndrome.
[0015] Preferably, the inhibitor comprises siRNA.
[0016] The present invention also provides a siRNA for interfering with PEBP4 gene expression, wherein the sense strand of the siRNA is shown as SEQ ID NO:11, and the antisense strand is shown as SEQ ID NO:12.
[0017] The present invention also provides the use of the siRNA in preparing medicines or reagents for treating porcine reproductive and respiratory syndrome.
[0018] The present invention also provides the application of PEBP4 gene in breeding of gene-edited pigs resistant to porcine reproductive and respiratory syndrome.
[0019] Compared with the prior art, the present invention has the following beneficial effects:
[0020] The present invention finds that overexpression of PEBP4 protein promotes PRRSV replication, and by designing and screening siRNA that interferes with PEBP4 gene expression, PEBP4 protein expression can be specifically knocked down to effectively control PRRSV infection, indicating that PEBP4 protein is an important host target related to PRRSV replication. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 This is the result of qRT-PCR detection of the effect of overexpression of PEBP4 on the expression level of PRRSV ORF7 mRNA;
[0022] Figure 2 This is the result of Western blot detection of the effect of overexpression of PEBP4 on the expression of PRRSV N protein;
[0023] Figure 3 This is the result graph of the effect of PEBP4-Flag transfection on the PRRSV titer in the culture supernatant of Marc-145 cells;
[0024] Figure 4 This is the result of qRT-PCR screening of siRNA that can effectively knock down PEBP4 gene expression in PAM cells;
[0025] Figure 5 This is the result of Western blot screening for siRNA that can effectively knock down PEBP4 protein expression in PAM cells;
[0026] Figure 6 This is the result of qRT-PCR detection of the effect of interfering with PEBP4 in PAMs cells on the expression level of PEBP4 mRNA;
[0027] Figure 7 This is the result of qRT-PCR detection of the effect of interfering with PEBP4 in PAMs cells on the expression of PRRSV ORF7mRNA;
[0028] Figure 8 This figure shows the effect of transfected siRNA on the PRRSV titer in the culture supernatant of PAMs cells. DETAILED DESCRIPTION
[0029] The present invention provides the use of overexpressed PEBP4 protein in promoting the proliferation of PRRSV.
[0030] In the present invention, the method for overexpressing PEBP4 protein comprises the following steps: constructing a plasmid for overexpressing PEBP4 protein, and transfecting the plasmid into cells to achieve overexpression of PEBP4 protein. The plasmid is PEBP4-Flag, and the PEBP4-Flag uses pCAGGS as the initial vector, and a gene fragment expressing PEBP4 protein is cloned between the SacI and NheI restriction sites on the pCAGGS vector.
[0031] The present invention also provides a plasmid for overexpressing PEBP4 protein. The plasmid is PEBP4-Flag. The PEBP4-Flag uses pCAGGS as an initial vector, and a gene fragment expressing PEBP4 protein is cloned between the SacI and NheI restriction sites on the pCAGGS vector.
[0032] The invention also provides application of the plasmid in promoting the proliferation of PRRSV.
[0033] The present invention also provides the use of a PEBP4 protein expression inhibitor in the preparation of a drug or reagent for treating porcine reproductive and respiratory syndrome. In the present invention, the inhibitor includes siRNA.
[0034] The present invention also provides a siRNA for interfering with PEBP4 gene expression, wherein the sense strand of the siRNA is as shown in SEQ ID NO: 11, which is CUAUGCAGGAACCUAGAAGUUTT, and the antisense strand is as shown in SEQ ID NO: 12, which is AACUUCUAGGUUCCUGCAUAGTT.
[0035] The present invention also provides the use of the siRNA in preparing medicines or reagents for treating porcine reproductive and respiratory syndrome.
[0036] The present invention also provides the application of PEBP4 gene in breeding of gene-edited pigs resistant to porcine reproductive and respiratory syndrome.
[0037] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.
[0038] The experimental materials used in the present invention are as follows:
[0039] African green monkey kidney epithelial cells (Marc-145), porcine alveolar macrophages (PAMs),
[0040] The specific steps for the preparation of porcine alveolar macrophages (PAMs) are as follows:
[0041] (1) Lung extraction: Select the lungs of healthy piglets aged 4 to 6 weeks in good growth condition. The piglets are killed by bleeding from the brachial artery plexus, the chest cavity is opened and the lung tissue is separated from the heart, and then the heart is removed, being careful not to damage the lungs.
[0042] (2) Use RPMI-1640 culture medium containing 0.1% double antibody (penicillin and streptomycin) to rinse the lungs and remove residual blood clots. Use alcohol cotton balls to wipe the surface of the lungs and place them on a clean bench.
[0043] (3) Inject 40-50 mL of RPMI-1640 culture medium containing 0.1% double-antibody (penicillin and streptomycin) into the lungs through the trachea. Gently and thoroughly rub the lungs. Filter the lavage fluid through three layers of filter paper. Repeat 4-5 times until the lavage fluid becomes clear.
[0044] (4) The filtered lavage fluid was dispensed into sterile 50 mL centrifuge tubes, centrifuged at 2000 rpm at 4°C for 15 min, and the supernatant was removed.
[0045] (5) Add 3 times the volume of red blood cell lysis buffer to the centrifuge tube and gently pipette to resuspend the cells. Open the water bath in advance, and then place the centrifuge tube in a 37°C water bath for lysis. When the liquid in the tube changes from bright red to gray-red, add RPMI-1640 containing 0.1% double antibody (penicillin and streptomycin) to terminate the lysis.
[0046] (6) Centrifuge at 2000 rpm for 15 min at 4°C and remove the supernatant. Add RPMI-1640 medium containing 0.1% double antibody (penicillin and streptomycin) again and gently pipette to resuspend the cells. After three washes, add 10-20 mL of RPMI-1640 nutrient solution containing 10% fetal bovine serum and 0.1% penicillin and streptomycin according to the cell volume and gently resuspend the cells.
[0047] (7) Calculate the number of cells by cell counting and dilute the cells to a density of 2.5 × 10 using RPMI-1640 nutrient solution containing 10% fetal bovine serum and 0.1% penicillin-streptomycin. 6 The cell suspension was added into a 24-well cell plate at 500 μL / well and cultured in a 37°C 5% CO2 incubator for 3-6 h. Subsequent experiments were performed after the cells adhered to the wall.
[0048] The highly pathogenic PRRSV strain BB0907 (GenBank: HQ315835.1) was used in all experiments and is named PRRSV in this article. It was donated by Professor Jiang Ping of Nanjing Agricultural University.
[0049] Lipofectamine 3000 and TRIzol were purchased from Thermo Fisher Scientific;
[0050] IIQ RT SuperMix for qPCR (+g DNA wiper) and FastPure Gel DNAExtraction Mini Kit were purchased from Nanjing Novozyme Biotechnology Co., Ltd.;
[0051] Lipofectamine RNAiMAX Reagent was purchased from Thermo Fisher Scientific;
[0052] Green Premix Pro Taq HS qPCR Kit was purchased from Hunan Aikerui Bioengineering Co., Ltd.;
[0053] Nucleic acid extraction kit, protein lysis buffer, protease inhibitors, phosphatase inhibitors, and 5× SDS loading buffer were purchased from Shanghai Bio-Tech Biotechnology Co., Ltd.;
[0054] Ligation Protocol with T4 DNA Ligase was purchased from NEW ENGLAND Biolabs;
[0055] Plasmid extraction kit and BCA protein quantification kit were purchased from Solebao Biotechnology Co., Ltd.
[0056] PEBP4 polyclonal antibody (ab99468) was purchased from Abcam Plc;
[0057] 10-250 kDa protein marker, 12.5% PAGE gel rapid preparation kit, and skimmed milk powder were purchased from Shanghai Yazyme Biopharmaceutical Technology Co., Ltd.
[0058] Example 1
[0059] Construction of eukaryotic expression plasmid of porcine PEBP4
[0060] 1. Cell RNA extraction
[0061] Extract cellular RNA according to the instructions of the RNA extraction kit. The steps are as follows:
[0062] (1) Take the treated 24-well cell plate, add 200 μL TRIzol to each well and fully lyse for 5 min. Transfer the lysed PAMs cell mixture to an RNase-free EP tube.
[0063] (2) Add 500 μL of Buffer A to each tube, vortex for 10 seconds to mix thoroughly, and leave at room temperature for 10 minutes.
[0064] (3) Transfer the above sample to the adsorption column, centrifuge at 13000 r / min for 30 s, and discard the liquid in the collection tube.
[0065] (4) Add 600 μL of Buffer B to the adsorption column, centrifuge at 13,000 rpm for 30 seconds, and discard the liquid in the collection tube. Repeat this step once.
[0066] (5) Centrifuge the empty column at 13000 r / min for 2 min until the alcohol is completely evaporated.
[0067] (6) Transfer the adsorption column to a new 1.5 mL centrifuge tube, add 50 μL of Buffer C to the center of the centrifuge tube, let stand for 2 min, and centrifuge at 13,000 rpm for 30 s to obtain RNA.
[0068] 2. Synthesis of PEBP4 cDNA
[0069] The RNA extracted in step 1 was used to synthesize cDNA using HiScript reverse transcriptase. The reverse transcription system was as follows: 16 μL RNA template, 4 μL 5×RT SuperMix, and 20 μL total system. After vortexing and mixing, cDNA synthesis was performed in a PCR instrument. The reverse transcription program was as follows: 50°C, 15 min; 85°C, 5 s. The synthesized cDNA was stored at -20°C for later use.
[0070] Primers containing the full-length sequence of PEBP4 were designed using Primerpremer5 software based on PEBP4, and SacI and NheI restriction sites and protective bases were added to both ends of the primers, and a Flag tag sequence was connected to the 3' end (Table 1), and the target fragment was amplified by PCR.
[0071] Table 1 Fusion PCR primer sequences
[0072]
[0073] The PCR amplification system was as follows: PrimeSTAR Max Premix (2X), 25 μL; PEBP4-F, 1 μL; PEBP4-R, 1 μL; cDNA, 2 μL; ddH2O, Up to 50 μL.
[0074] After the PCR system was configured, centrifuged instantly, and placed in a PCR instrument, the reaction program was: 98°C, 1s; 98°C, 10s; 58°C, 5s; 72°C, 50s; 72°C, 5min. The three intermediate temperatures were used for 35 cycles.
[0075] 3. Recovery of PCR products
[0076] After PCR products were subjected to 1% agarose gel electrophoresis, DNA fragments were recovered using the Novozyme gel recovery kit. The specific steps were as follows:
[0077] (1) After DNA electrophoresis, cut out the gel containing the target DNA fragment and weigh the gel (excluding the weight of the empty tube). 100 mg of gel is equivalent to 100 μL, which is considered as a gel volume.
[0078] (2) Add an equal volume of Buffer GDP. Incubate at 50-55°C in a water bath for 7-10 min. Adjust the time appropriately according to the size of the gel to ensure that the gel is completely dissolved. Invert and mix twice during the water bath to accelerate the gelation process.
[0079] (3) Transfer the mixture to the FastPure DNAMini Columns-G adsorption column, centrifuge at 7000 rpm for 1 min, and discard the liquid in the collection tube.
[0080] (4) Add 300 μL of Buffer GDP to the adsorption column and let it stand for 1 min. Centrifuge at 12,000 rpm for 1 min and discard the liquid in the collection tube.
[0081] (5) Add 700 μL of Buffer GW (with anhydrous ethanol) to the adsorption column. Centrifuge at 12,000 rpm for 1 min and discard the liquid in the collection tube. Repeat this step once.
[0082] (6) Centrifuge the empty column at 12,000 rpm for 2 min to allow the alcohol to evaporate completely.
[0083] (7) Place the adsorption column in a 1.5 ml sterile centrifuge tube, add 20 μL of Elution Buffer to the center of the adsorption column, and place it for 2 minutes. Centrifuge at 12,000 rpm for 1 minute.
[0084] (8) The concentration of the recovered product was determined by NanoDrop2000 and the DNA was stored at -20°C for later use.
[0085] 4. Enzyme digestion and ligation of target fragment and vector
[0086] The gel-recovered product and pCAGGS vector were double-digested with the following enzyme system: cDNA / pCAGGS, 1.5 μg; 10× enzyme digestion buffer, 5 μL; SacI endonuclease, 0.75 μL; NheI endonuclease, 0.75 μL; ddH2O, Up to 50 μL.
[0087] Place the prepared enzyme digestion system into the PCR instrument and set the enzyme digestion system to: 37°C, 1h. Recover the target fragment and vector after enzyme digestion and determine the concentration of the recovered product. According to https: / / nebiocalculator.neb.com / , the target gene and vector after enzyme digestion are prepared into a connection system according to the ratio of target fragment to linear vector of 7:1: pCAGGS, 40ng; PEBP4, 48.45ng; T4 DNALigase, 1μL; T4 DNALigase Buffer (10×), 2μL; ddH2O, Up to 20μL.
[0088] Place the prepared ligation system into the PCR instrument and set the enzyme digestion system to: 25°C, 30 min; 65°C, 10 min.
[0089] 5. Conversion
[0090] (1) Add 5 μL of ligation product to 50 μL of DH5α competent cells, mix well, and incubate on ice for 30 min;
[0091] (2) Heat shock in a 42°C water bath for 90 seconds, then place in an ice bath for 2 minutes;
[0092] (3) After an ice bath, add 800 μL of LB without antibiotics and culture at 37°C in a shaker at 200 rpm for 45 min;
[0093] (4) Centrifuge at 12000 rpm for 1 min, discard the supernatant, add 100 μL of LB to resuspend the precipitate, spread the entire bacterial solution evenly on an LB plate containing ampicillin, and culture inverted in a 37°C bacterial incubator for 12 to 16 h.
[0094] 6. Bacterial liquid PCR identification
[0095] Four single colonies were randomly picked and placed in an EP tube containing 1 mL LB containing ampicillin resistance. After incubation at 37°C in a shaking incubator for 2 h, PCR identification was performed using Taq PCR Mix. The PCR system was as follows: 2×Taqmix, 12.5 μL; SacI-PEBP4, 1 μL; PEBP4-Flag-NheI, 1 μL; cDNA, 2 μL; ddH2O, Up to 25 μL.
[0096] Place the prepared system into the PCR instrument and set the reaction system as follows: 95°C, 5 min; 95°C, 30 s; 58°C, 30 s; 72°C, 50 s; 72°C, 10 min.
[0097] The amplified PCR products were subjected to 2% agarose gel electrophoresis and the results were observed under a nucleic acid imaging instrument. The bacterial solution identified as positive by PCR was sent to Shanghai Shenggong Bioengineering Technology Service Co., Ltd. for sequencing and expansion culture.
[0098] Example 2
[0099] Plasmid extraction
[0100] Plasmid extraction was performed according to the instructions of the Solebow Plasmid Extraction Kit, and the steps are as follows:
[0101] (1) Add the bacterial culture identified as positive in Example 1 into an EP tube, centrifuge at 12,000 rpm for 1 min, discard the supernatant, repeat multiple times, and collect the bacterial precipitate into an EP tube;
[0102] (2) Add 250 μL of Solution I to the centrifuge tube containing the bacterial cell pellet to thoroughly suspend the bacterial cell pellet;
[0103] (3) Add 250 μL of Solution II to the centrifuge tube and gently invert it upside down 6 to 8 times to fully lyse the bacteria;
[0104] (4) Add 350 μL of Solution III to the centrifuge tube, gently invert it upside down 6 to 8 times, mix thoroughly, and centrifuge at 12,000 rpm for 10 min;
[0105] (5) Add the supernatant obtained above to the adsorption column, place at room temperature for 2 minutes, centrifuge at 12000 rpm for 1 minute, and discard the waste liquid;
[0106] (6) Add 600 μL of rinse solution I to the adsorption column, centrifuge at 12000 rpm for 1 min, and discard the waste liquid;
[0107] (7) Add 700 μL of rinse solution II to the adsorption column, centrifuge at 12000 rpm for 1 min, and discard the waste liquid;
[0108] (8) Add 500 μL of rinse solution II to the adsorption column, centrifuge at 12,000 rpm for 1 min, and discard the waste liquid;
[0109] (9) Centrifuge the empty column at 12,000 rpm for 2 min to completely evaporate the alcohol;
[0110] (10) Place the adsorption column in a clean centrifuge tube and drop 50–200 μL of the eluent preheated in a 65°C water bath into the center of the adsorption membrane. Allow to stand at room temperature for 2 min and centrifuge at 12,000 rpm for 1 min.
[0111] Example 3
[0112] Plasmid transfection
[0113] When the confluence of Marc-145 cells in the 24-well plate reaches 80%, transfection can be performed. Plasmid transfection is performed according to the instructions of Lipofectamine3000. The specific steps are as follows:
[0114] (1) Solution A: Add 1.5 μL Lipofectamine 3000 to 23.5 μL serum-free DMEM;
[0115] (2) Solution B: Take 1 μg of the plasmid extracted in Example 2 and dilute it to 23.5 μL with serum-free DMEM, then add 2 μL of P3000TM and vortex to mix;
[0116] (3) Slowly add solution A to solution B, mix gently with your fingertips, centrifuge briefly, and let stand at room temperature for 15 min;
[0117] (4) Replace the cell culture medium in the 24-well plate;
[0118] (5) The mixed plasmid-liposome mixture was added dropwise to the cell culture medium using a pipette, and the culture was continued in a 37°C, 5% CO2 incubator for 24 hours. 0.1 moi of PRRSV strain BB0907 virus solution was inoculated 24 hours after transfection. At the same time, Marc-145 cells transfected with the pCAGGS vector not connected to PEBP4 and inoculated with 0.1 moi of PRRSV strain BB0907 virus solution were set as a control, which was the empty group.
[0119] Example 4
[0120] Detection of PRRSV ORF7 mRNA expression in Marc-145 cells after plasmid transfection by fluorescence quantitative PCR (qRT-PCR)
[0121] In Example 3, RNA extraction and cDNA acquisition in Marc-145 cells inoculated with virus solution and MARC-145 cells in the empty vector group were carried out according to Example 1. qRT-PCR was performed according to the instructions of the Green Premix Pro Taq HSqPCR Kit. The reaction system was 20 μL: SYBR Green Pro Taq HS Premix (2×) 10 μL, PCR upstream primer 0.5 μL, PCR downstream primer 0.5 μL, cDNA template 2 μL, ddH2O7 μL. Fluorescence quantitative PCR was performed on the Mx3005P fluorescence quantitative PCR instrument. The reaction conditions were: 95°C denaturation for 3 min, 95°C denaturation for 30 s, 58°C annealing for 30 s, 72°C extension for 30 s, 40 cycles, and the melting curve was based on the system default program. The specific primers for fluorescence quantitative PCR are shown in Table 2 below.
[0122] Table 2 Specific primers for fluorescence quantitative PCR
[0123]
[0124] The results of qRT-PCR were analyzed using 2-DDCt calculation method, and the calculation method was as follows: DCt of experimental group = Ct of target gene of experimental group - Ct of internal reference gene of experimental group; DCt of control group = Ct of target gene of control group - Ct of internal reference gene of control group; DDCt = DCt of experimental group - DCt of control group; and then 2-DDCt was calculated.
[0125] Experimental results: Figure 1 As shown, the expression level of PRRSV ORF7 mRNA in the PEBP4-Flag group was significantly higher than that in the empty vector group, indicating that PRBP4 promotes the expression of viral genes of PRRSV in Marc-145 cells.
[0126] Example 5
[0127] Western blot detection of PRRSV N protein expression in Marc-145 cells after plasmid transfection
[0128] (1) Sample preparation: Wash the surface of the Marc-145 cells transfected with plasmid and inoculated with virus solution in Example 3 and the Marc-145 cells in the empty group in the 24-well plate with PBS three times, add 120 μL / well RIPA cell lysis solution, and lyse the cell plate on ice for 30 minutes, shaking every 5 minutes. Collect the lysed cell samples into EP tubes, centrifuge at 4°C, 12000 rpm for 10 minutes, and collect the supernatant.
[0129] (2) Take out 100 μL of supernatant from each sample as the positive control (Input) and place it in a new EP tube, mark it, and store it at -20°C for future use.
[0130] (3) Add 1 μg of monoclonal antibody to the remaining supernatant and incubate at 4°C with slow shaking for 8 h.
[0131] (4) Add 40 μL of Protein A+G agarose beads and continue to incubate with slow shaking at 4°C for 3 h.
[0132] (5) Centrifuge at 2500 rpm for 5 min, wash with pre-cooled PBS, and discard the supernatant. Repeat this step 4 times.
[0133] (6) Add 100 μL of pre-cooled PBS to resuspend the precipitate. Add 5× Loading Buffer, boil at 100°C for 10 min, and perform Western blot to determine the expression of PRRSV N protein in the cells.
[0134] Experimental results: Figure 2 The expression of PRRSVN protein in the PEBP4-Flag group was significantly higher than that in the empty vector group, indicating that PRBP4 promotes the expression of PRRSV protein in Marc-145 cells.
[0135] Example 6
[0136] TCID 50 Determination of the effect of PEBP4-Flag transfection on PRRSV titer in the supernatant of Marc-145 cells
[0137] 1. Plate: Add an appropriate amount of DMEM medium containing 10% fetal bovine serum to the Marc-145 cells digested with trypsin and adjust the density to 1×10 5 pc / ml, added to 96-well cell culture plates to allow the cells to grow into a monolayer;
[0138] 2. Dilute the collected virus-containing cell supernatant in a sterile EP tube using serum-free DMEM medium for 10-fold dilutions. -1 ~10 -10 , each dilution should be thoroughly mixed;
[0139] 3. Inoculate into Marc-145 cells in descending dilution order, inoculate one vertical row of 8 wells for each dilution, inoculate 100 μL per well, and take two vertical rows as normal cell controls;
[0140] 4. Observe and record the results daily starting from the second day for 5 to 7 days;
[0141] 5. Refer to the Reed-Muench method for TCID 50 Perform calculations.
[0142] Experimental results: Figure 3 As shown, 24 hours after cells transfected with empty pCAGGS and PEBP4-Flag were infected with PRRSV BB0907 strain, the PRRSV virus titer in the cell culture supernatant showed that the PEBP4-Flag transfected group was significantly higher than that of the empty pCAGGS group, indicating that PRBP4 promotes the proliferation of PRRSV in Marc-145 cells.
[0143] Example 7
[0144] siRNA interference fragment synthesis and screening:
[0145] Small interfering RNA (siRNA) targeting the porcine PEBP4 gene and the control (NC) were synthesized by Shanghai Jima Pharmaceutical Technology Co., Ltd. The sequences of the siRNAs are shown in Table 3.
[0146] Table 3 siRNA sequences
[0147]
[0148]
[0149] PAMs cells were cultured in 24-well plates, and the cell confluence was 80%. 10 nmol of interference fragments were transfected into PAMs cells. Cell nucleic acid samples and protein samples were collected 24 hours after transfection. The expression of PEBP4 mRNA was detected by qRT-PCR, and the expression of PEBP4 protein was detected by Western blotting. Effective interference fragments were identified.
[0150] Experimental results: Figure 4Compared with NC, the three interference fragments can reduce the gene expression of PEBP4, but si-PEBP4-1 has the most obvious effect.
[0151] like Figure 5 As shown in the figure, compared with NC, the protein expression of PEBP4 was significantly reduced by si-PEBP4-1, and the other two interference fragments had no obvious effect on the expression of PEBP4 protein. Therefore, si-PEBP4-1 is the more effective of the three interference fragments and can effectively knock down the gene and protein expression of PEBP4 in PAM cells.
[0152] Example 8
[0153] Effect of PEBP4 knockdown in PAMs cells on PRRSV proliferation
[0154] 1. PEBP4 siRNA transfection and cell inoculation
[0155] (1) Plating: porcine alveolar macrophages were isolated from the lung tissue of 6-week-old piglets, and the cells were counted and plated, and cultured in a 37°C 5% CO2 incubator;
[0156] (2) Transfection: The transfection reagent is Lipofectamine RNAiMAX Reagent from Life Tech, and transfection is performed according to the operating procedures of the transfection reagent. Prepare the transfection mixture 12 hours after plating (dissolve the si-PEBP4-1 with the best interference effect obtained in Example 7 and Lipofectamine RNAiMAX Reagent in Opti-MEM respectively, and then mix the two) and incubate at room temperature for 5 minutes. Take the 24-well plate out of the incubator, wash it with PBS and replace it with Opti-MEM, add the mixture dropwise, shake and mix, and place it in a cell culture incubator for culture;
[0157] (3) Virus inoculation: 24 h after transfection, HP-PRRSV BB0907 strain was inoculated at 0.1 MOI, according to the formula PFU = number of cells × MOI = 0.7 × TCID 50 Calculate the required virus solution. Take out the 24-well plate, wash it with PBS, add the virus diluent, incubate it at 37℃ for 1 hour, discard the virus solution, and replace it with 1640 medium containing 3% serum;
[0158] (4) Sampling: 24 h after infection, cell samples and cell culture supernatant were collected and stored at -80°C. Cell samples were used to detect the relative expression levels of PEBP4 and PRRSV ORF7 genes in cells, and cell culture supernatant was used to detect the number of copies of the viral genome released into the culture supernatant and the virus titer.
[0159] 2. RT-qPCR detection of relative expression levels of PEBP4 and PRRSV ORF7 mRNA in PAMs
[0160] RNA extraction and cDNA acquisition refer to Example 1. qRT-PCR was performed according to the instructions of Green Premix Pro TaqHS qPCR Kit. The reaction system was 20 μL: SYBR Green Pro Taq HS Premix (2×) 10 μL, PCR upstream primer 0.5 μL, PCR downstream primer 0.5 μL, cDNA template 2 μL, ddH2O7 μL. Fluorescence quantitative PCR was performed on the Mx3005P fluorescence quantitative PCR instrument. The reaction conditions were: 95°C denaturation for 3 min, 95°C denaturation for 30 s, 58°C annealing for 30 s, 72°C extension for 30 s, 40 cycles, and the melting curve was performed according to the system default program.
[0161] The specific primers for fluorescence quantitative PCR are shown in Table 4 below.
[0162] Table 4 Specific primers for fluorescence quantitative PCR
[0163]
[0164]
[0165] The results of qRT-PCR were analyzed using 2-DDCt calculation method, and the calculation method was as follows: DCt of experimental group = Ct of target gene of experimental group - Ct of internal reference gene of experimental group; DCt of control group = Ct of target gene of control group - Ct of internal reference gene of control group; DDCt = DCt of experimental group - DCt of control group; and then 2-DDCt was calculated.
[0166] Experimental results: Figure 6 The gene expression of PEBP4 was reduced by the interference fragment si-PEBP4-1, which again indicated that PEBP4 was significantly knocked down by si-PEBP4-1 in this experiment.
[0167] like Figure 7 As shown in the figure, the expression level of PRRSV ORF7 mRNA in cells transfected with si-PEBP4-1 was significantly lower than that in the group transfected with irrelevant interference fragments, indicating that knocking down PEBP4 inhibited the expression of viral genes of PRRSV in PAMs cells.
[0168] 3. TCID 50 Determination of PRRS virus titer in cell culture supernatant
[0169] (1) Plating: Add an appropriate amount of DMEM medium containing 10% fetal bovine serum to the Marc-145 cells digested with trypsin and adjust the density to 1×10 5 pc / mL, added to 96-well cell culture plates, and allowed the cells to grow into a monolayer;
[0170] (2) The collected virus-containing cell supernatant was diluted 10 times in a sterilized EP tube using serum-free DMEM medium. -1 ~10 -10 , each dilution should be thoroughly mixed;
[0171] (3) Inoculate Marc-145 cells in descending dilution order, inoculate 8 wells in a vertical row for each dilution, inoculate 100 μL in each well, and take two vertical rows as normal cell controls;
[0172] (4) Observe and record the results daily starting from the second day for 5 to 7 days;
[0173] (5) Refer to the Reed-Muench method for TCID 50 Perform calculations.
[0174] Experimental results: Figure 8 As shown, when HP-PRRSV BB0907 strain was infected after transfection of siRNA targeting PEBP4 in PAMs, the virus titer in the cell culture supernatant was significantly lower than that of the irrelevant interference fragment group at 24hpi, indicating that knocking down PEBP4 inhibited the proliferation of PRRSV in PAMs cells.
[0175] It can be seen from the above examples that the expression of PEBP4 protein in the present invention promotes PRRSV replication, and interfering with PEBP4 protein expression can inhibit PRRSV replication. PEBP4 protein is an important host target related to PRRSV replication, and PRRSV infection can be effectively controlled by inhibiting PEBP4 protein expression.
[0176] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. Use of a PEBP4 gene expression inhibitor in the preparation of an agent for inhibiting porcine reproductive and respiratory syndrome virus, characterized in that: The inhibitor comprises siRNA; the sense strand of the siRNA is shown as SEQ ID NO:11, and the antisense strand is shown as SEQ ID NO:12.
Citation Information
Patent Citations
Porcine reproductive and respiratory syndrome resisting Marc-145 cell line as well as preparation method and application thereof
CN108103099A
Functions and uses of phosphatidylethanolamine binding protein 4
WO2009030087A1
